Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President…

A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene…

The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical production back to Europe has hit a wall,…

Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique…

The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does…

Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by…

Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for…

Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement…

Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge…

Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its…

Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and…

One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically…